在多发性硬化症中减缓和停止疾病修饰疗法
Robert H Gross1,2, John Corboy3
1Department of Neurology, University of Colorado School of Medicine, 12631 East 17thAvenue, Mail Stop F727, Aurora, CO, 80045, USA. Robert.Gross@cuanschutz.edu.
Current neurology and neuroscience reports
|July 12, 2024
概括
患有多发性硬化症 (MS) 的老年人可能会从降低或停止疾病修饰疗法 (DMT) 中受益. 最近的研究根据年龄和疾病活性决定改变MS治疗的决定.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 老年病的医生 老年病的医生
背景情况:
- 长期使用疾病修饰疗法 (DMT) 是治疗多发性硬化症 (MS) 的标准.
- 与年龄相关的变化,包括免疫衰变,改变了老年多发性硬化症患者中DMT的风险-益处概况.
研究的目的:
- 审查最近关于MS DMTs降级和停止的研究.
- 评估年龄和其他因素对MS中改变DMT的结果的影响.
主要方法:
- 对观察性和干预性研究的审查.
- 分析影响DMT减缓或停止使用的患者结果的因素.
主要成果:
- 最近的研究提供了关于DMT缓解或停止治疗后患者结果的见解.
- 患者年龄,DMT类型和最近的疾病活动等因素会影响结果.
结论:
- 在MS中,基于证据的方法正在出现,用于降级和停止决策.
- 需要进一步的研究,以充分解决关于老年多发性硬化症患者DMT修饰的剩余问题.
相关概念视频
Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Desensitization and Tachyphylaxis
1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K
Parkinson's Disease: Treatment
251
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
251


